West Palm Beach, FL, United States of America

Carlos Coito

USPTO Granted Patents = 26 (Patent Applications = 13)

CIPO Patents = 12 (Patent Applications = 4)

EPO Patents = 16 (Patent Applications = 20)

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 65(Granted Patents)

Company Filing History:

The Scripps Research Institute

patents

where one patent can have more than one assignee

Years Active: 2012-2022

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11408004 - Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT) (2022-08-09),

2. 11390868 - Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity (2022-07-19),

3. 10995334 - Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2 (2021-05-04),

4. 10793857 - Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA (2020-10-06),

5. 10604755 - Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene (2020-03-31),

6. 10519448 - Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF (2019-12-31),

7. 10465192 - Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 (2019-11-05),

8. 10435690 - Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA (2019-10-08),

9. 10214745 - Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF (2019-02-26),

10. 10113166 - Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity (2018-10-30),

11. 9902958 - Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG (2018-02-27),

12. 9873873 - Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA (2018-01-23),

13. 9834769 - Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 (2017-12-05),

14. 9771579 - Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA (2017-09-26),

15. 9725756 - Treatment of 'C terminus of HSP7O-interacting protein' (CHIP) related diseases by inhibition of natural antisense transcript to CHIP (2017-08-08),

Title: Innovations and Contributions of Carlos Coito

Introduction

Carlos Coito, based in West Palm Beach, Florida, is a prominent inventor with an impressive portfolio of 26 patents. His groundbreaking work focuses on the modulation of genes and their roles in various diseases, demonstrating a commitment to advancing medical science through innovative technologies.

Latest Patents

Among his latest patents is the invention targeting the treatment of Sirtuin (SIRT) related diseases via inhibition of natural antisense transcripts to Sirtuins. This invention involves antisense oligonucleotides that specifically modulate the expression and functionality of Sirtuins, with applications in the treatment of disorders linked to their expression. Another significant patent addresses diseases associated with Filaggrin (FLG) by employing antisense oligonucleotides that influence the expression and activity of Filaggrin. This work aims to provide new therapeutic strategies for ailments related to FLG expression, highlighting his focus on genetic modulation as a means to combat disease.

Career Highlights

Throughout his career, Carlos Coito has made substantial contributions to the fields of genetics and medical research. He has worked with notable companies, including Curna, Inc. and The Scripps Research Institute. His experience in these institutions has been pivotal in shaping his approach to patent development and innovation in therapeutic solutions.

Collaborations

Carlos has collaborated with several esteemed professionals in his field, including Joseph Collard and Olga Khorkova Sherman. These partnerships have enriched his research, fostering a collaborative environment that stimulates the ideation and execution of cutting-edge inventions.

Conclusion

Carlos Coito's innovative contributions and extensive patent portfolio underscore his significant impact on medical science and genetic research. His dedication to exploring new therapeutic avenues continues to inspire advancements that may one day transform treatments for numerous diseases. As technology evolves, his work will undoubtedly play a critical role in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.